Deals

Myovant’s deal with Pfizer for $650M up front is the latest sign women’s health is back

Pfizer’s partnership with Myovant sends another signal that plenty of opportunity still exists in women’s health, despite recent pharma exits.

In teaming up with Pfizer Inc.